Amycretin
Overview
Amycretin is a dual agonist targeting both the amylin and calcitonin receptors, designed as a peptide therapeutic for obesity. Amylin receptor activation reduces food intake and delays gastric emptying, while calcitonin receptor engagement may further contribute to appetite suppression and weight loss. The compound represents a novel approach distinct from GLP-1-based therapies.
Key Research Findings
Early-phase clinical data released in 2023 indicated dose-dependent weight loss in individuals with obesity. The safety profile was acceptable, with nausea being the most frequently reported adverse event. Further trials are needed to determine long-term efficacy and optimal dosing.
Subcutaneous injection
In Clinical Trials
Interested in Amycretin?
Find a verified provider experienced with Amycretin protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Amycretin ProviderRelated Peptides
Semaglutide (Ozempic/Wegovy)
FDA ApprovedA glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and acts on hypothalamic GLP-1 receptors to reduce appetite. Its fatty acid side chain enables albumin binding, extending its half-life to approximately 7 days.
Tirzepatide (Mounjaro/Zepbound)
FDA ApprovedA first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways simultaneously, producing superior glycemic control and weight loss compared to selective GLP-1 RAs. The dual mechanism enhances insulin sensitivity and lipid metabolism beyond what either pathway achieves alone.
Retatrutide
In Clinical TrialsAn investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds thermogenic energy expenditure and hepatic lipid mobilization to the incretin-mediated appetite suppression and insulin sensitization. This triple mechanism addresses obesity through complementary metabolic pathways.
AOD-9604
InvestigationalA modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604 retains the lipolytic activity of hGH without its growth-promoting or diabetogenic effects. It stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from the GH receptor, acting on beta-3 adrenergic receptors in adipose tissue.